INTRODUCTION
============

Bone morphogenetic protein 4 (BMP4) is a member of transforming growth factor-β (TGF-β) superfamily of secreted signaling proteins. It controls via Smad1/5/8 the transcription of tissue-specific target genes during early development and adult tissue homeostasis ([@b1-bmb-52-403]). Ventx1.1 (PV.1, Xvent-1b) and Xcad2, homeobox transcription factors, are downstream target genes of BMP4/Smad1 signaling in *Xenopus* embryos ([@b2-bmb-52-403], [@b3-bmb-52-403]). Ventx1.1 acts as a transcriptional repressor to inhibit the expression of neural and organizer-specific genes, including *FoxD5b*, *Zic3*, *NCAM*, *Otx2*, *Gsc*, *Noggin*, and *Chordin* ([@b2-bmb-52-403], [@b4-bmb-52-403]--[@b6-bmb-52-403]). Thus, the ectopic expression of *Ventx1.1* causes ventralized and headless embryonic phenotypes. Xcad2 is a transcriptional activator that can induce the expression of *BMP4* as well as of its downstream target genes such as *Ventx1.1*, *Ventx1.2*, *Ventx2.1*, and *Xpo* ([@b3-bmb-52-403]). However, it inhibits the expression of organizer-specific genes *Gsc*, *Xlim1*, and *Otx2* independently of BMP signaling ([@b3-bmb-52-403]). Recently, it has been shown that the BMP4/Smad1 pathway can synergize with the FGF/Xbra pathway to activate *Ventx1.1* transcription, resulting in neural inhibition in *Xenopus* embryos ([@b7-bmb-52-403], [@b8-bmb-52-403]). In line with this, 5′-flanking upstream region of *Ventx1.1* contains direct *cis*-acting responsive elements for several transcription factors, including Smad1, Xbra, and OAZ. While the repressive effects of Ventx1.1 on the expression of various neural and organizer genes have been demonstrated, its global binding sites remain to be characterized. Thus, we sought to identify genome-wide occupancy pattern of Ventx1.1 in *Xenopus* gastrulae using chromatin immunoprecipitation (ChIP)-Seq. As expected, our analysis revealed that neural and organizer-specific genes were included in the list of candidates whose 5′-flanking region might contain binding sites for Ventx1.1. Notably, Ventx1.1 could also bind to its own 5′-flanking upstream sequence. In this study, we have identified direct response element for Ventx1.1 to down-regulate its own transcription in a negative feedback loop. Intriguingly, Ventx1.1 and Xcad2, an activator of *Ventx1.1* transcription, competitively co-occupied the common binding site within the 5′-promoter region of *Ventx1.1*. These results provide an insight into the mechanism by which the expression level of *Ventx1.1* is fine-tuned spatially and temporally during dorsoventral patterning of *Xenopus* embryo.

RESULTS AND DISCUSSION
======================

Overexpression of Ventx1.1 inhibits the expression of ventral-specific genes
----------------------------------------------------------------------------

Our ChIP-Seq analysis showed that Ventx1.1 might directly bind to not only its own 5′-flanking sequence but that of *Ventx1.2* or *Ventx2.1* in *Xenopus* gastrula-stage embryos (data not shown). Thus, we first examined the effects of the gain-of-Ventx1.1 function on the expression of ventral-specific genes. As shown in [Fig. 1A, B](#f1-bmb-52-403){ref-type="fig"}, overexpression of *Ventx1.1* reduced its own endogenous expression and that of other ventral genes such as *Ventx1.2* and *Ventx2.1* in animal caps as analyzed by RT-PCR. In contrast, Ventx1.1 had no effect on the expression of *BMP4*. Given that these ventral genes are BMP4-induced targets ([@b9-bmb-52-403]), these results suggest that Ventx1.1 can down-regulate the expression of ventral-specific genes, including itself, in a BMP-independent manner.

Mapping of Ventx1.1 response element in its own promoter
--------------------------------------------------------

Negative autoregulation of transcription of a gene can restrict its expression level and/or activity, contributing to proper patterning of embryonic body axis ([@b10-bmb-52-403], [@b11-bmb-52-403]). Of potential candidate genes whose 5′-promoter region might contain Ventx1.1-responsive elements, we chose *Ventx1.1* itself for this study to gain further mechanistic insight into the regulation of its expression. Analysis of the 5′-flanking genomic sequence (2.5 kb) of *Ventx1.1* revealed 13 putative cis-acting response elements for Ventx1.1 ([Supplementary Table 1](#s1-bmb-52-403){ref-type="supplementary-material"}). To identify functional Ventx1.1 response elements (VREs) within the flanking region, we generated luciferase reporter constructs containing serially-deleted *Ventx1.1* promoter fragments ([Fig. 2A](#f2-bmb-52-403){ref-type="fig"}) and then examined the effects of overexpression of *Ventx1.1* on their promoter activities. Co-expression of *Ventx1.1* significantly reduced the activity of the −2525-bp construct ([Fig. 2B](#f2-bmb-52-403){ref-type="fig"}), indicating the presence of functional VREs in the full 5′-flanking sequence. Of note, the inhibitory effect of *Ventx1.1* on the reporter activity became relatively stronger as gastrulation proceeded (0.7-fold at stage 11.5 as compared with 0.5-fold at stage 10.5). While Ventx1.1-mediated repression of the reporter activity was still observed when the promoter fragment was reduced to −951 bp, this effect was lost upon deletion to −399 bp ([Fig. 2C](#f2-bmb-52-403){ref-type="fig"}). This suggests that Ventx1.1 response elements are located between −951 bp and −399 bp. The promoter region between −951 bp and −399 bp contains two putative Ventx1.1 binding sites \[VRE1, −626 bp to −621 bp (GATTTG) and VRE2, −697 bp to −692 bp (GATTTT)\] ([Supplementary Table 1](#s1-bmb-52-403){ref-type="supplementary-material"}). To determine whether these two potential sites could confer Ventx1.1 responsiveness, we substituted 5′-GGGG-3′ for the core sequence 5′-ATTT-3′ in the putative VRE1 or VRE2 in the −951-bp promoter construct and measured activities of these mutated reporters in the absence or presence of Ventx1.1. Interestingly, mutation of VRE1 (−951 bp-mVRE1), but not of VRE2 (−951 bp-mVRE2), resulted in a significant decrease (13-fold) in the basal promoter activity of the −951-bp construct even in the absence of Ventx1.1 ([Fig. 2D, E](#f2-bmb-52-403){ref-type="fig"}), suggesting that the putative VRE1 might also act as a binding site for a transcriptional activator that could positively regulate *Ventx1.1* expression. Furthermore, unlike the wild-type −951-bp reporter construct, the −951-bp-mVRE1 reporter was unresponsive to co-injected *Ventx1.1* ([Fig. 2E](#f2-bmb-52-403){ref-type="fig"}), supporting the functionality of VRE1. In contrast, the −951-bp-mVRE2 promoter fragment still exhibited significantly reduced activity upon co-expression of *Ventx1.1* ([Fig. 2E](#f2-bmb-52-403){ref-type="fig"}), indicating that the putative VRE2 might not be relevant to inhibitory autoregulation of *Ventx1.1* expression. In addition, we performed ChIP-PCR analysis to test whether Ventx1.1 might indeed bind to the promoter region encompassing VRE1. As shown in [Fig. 2F](#f2-bmb-52-403){ref-type="fig"}, anti-Flag antibody-mediated ChIP followed by PCR showed that Flag-Ventx1.1 was highly enriched in the promoter fragment containing VRE1. Taken together, these results suggest that Ventx1.1 acts as a repressor of its own transcription by binding to the response element present in its own promoter.

Xcad2 activates Ventx1.1 transcription by binding to VRE1
---------------------------------------------------------

As shown above, the −951-bp promoter with VRE1 mutation displayed significantly reduced basal activity, suggesting that the response element might be co-occupied by a transcriptional activator as well as Ventx1.1 itself as a repressor. It is known that the expression pattern of *Xcad2* overlaps with that of *Xvent-1* in *Xenopus* gastrulae and that Xcad2 can positively regulate the expression of ventral-specific genes including *Ventx1* and *Ventx2* ([@b3-bmb-52-403], [@b12-bmb-52-403]). Thus, Xcad2 might be a potential candidate capable of binding to VRE1 to activate *Ventx1.1* transcription. As expected, forced expression of *Xcad2* increased the transcription of ventral genes such as *Ventx1.1*, *Ventx1.2* and *Ventx2.1* and *BMP4*, in animal caps as analyzed by RT-PCR ([Fig. 3A](#f3-bmb-52-403){ref-type="fig"}). Conversely, overexpression of *Ventx1.1* down-regulated basal and Xcad2-induced levels of expression of ventral genes except *BMP4*. These results suggest that Xcad2 can act as a transcriptional activator of ventral genes to counteract inhibitory effects of Ventx1.1.

Response elements for caudal-type transcription factors such as Xcad2 have a core consensus sequence, 5′-ATTT-3′ ([@b13-bmb-52-403]--[@b15-bmb-52-403]). Note that VRE1 in the promoter region of *Ventx1.1* also contains this core sequence ([Supplementary Table 1](#s1-bmb-52-403){ref-type="supplementary-material"}). Consistent with this, overexpression of *Xcad2* increased the activity of the −951-bp construct to \~3-fold over the basal level, but had no effect on the activity of its version with VRE1 mutation ([Fig. 3B](#f3-bmb-52-403){ref-type="fig"}). These results indicate that Xcad2 could up-regulate *Ventx1.1* expression by occupying VRE1 within its promoter region. Thus, we next examined whether Xcad2 might indeed bind to VRE1 to activate *Ventx1.1* transcription. As shown in [Fig. 3C](#f3-bmb-52-403){ref-type="fig"}, overexpressed Xcad2 associated with VRE1 in the promoter region of *Ventx1.1* as analyzed by ChIP-PCR. In addition, co-expression of *Ventx1.1* caused displacement of Xcad2 from the DNA binding site ([Fig. 3C, D](#f3-bmb-52-403){ref-type="fig"}), suggesting that VRE1 might be shared by both of the transcription factors. In line with this, overexpression of *Xcad2* induced an increase in the activity of the −951-bp promoter fragment, which could be abrogated by co-expression of *Ventx1.1* ([Fig. 3E](#f3-bmb-52-403){ref-type="fig"}). Taken together, these results indicate that Xcad2 binds to VRE1 to up-regulate *Ventx1.1* transcription.

Ventx1.1 and Xcad2 competitively occupy VRE1 to regulate Ventx1.1 transcription
-------------------------------------------------------------------------------

Co-occupancy of a promoter region by two transcription factors suggests their competition in control of gene expression. Thus, we further investigated whether Ventx1.1 and Xcad2 could interfere with each other in binding to VRE1. As demonstrated by ChIP-PCR experiments, overexpressed Ventx1.1 could bind to its own promoter containing VRE1, while such occupancy by Ventx1.1 was gradually decreased by increasing co-expression of *Xcad2* ([Fig. 4A, B](#f4-bmb-52-403){ref-type="fig"}). In addition, the association between Xcad2 and *Ventx1.1* promoter was markedly inhibited by co-expression of *Ventx1.1* ([Fig. 4C, D](#f4-bmb-52-403){ref-type="fig"}). These results suggest that Xcad2 and Ventx1.1 can competitively occupy the *cis*-acting response element within the promoter region of *Ventx1.1* to regulate its transcription in an opposite way.

Ventx1.1 functions as a transcriptional repressor to exert anti-organizer and anti-neural activities, mimicking ventralizing effects of BMP4/Smad1 signaling ([@b2-bmb-52-403], [@b4-bmb-52-403]). *Ventx1.1* is a direct target of the BMP4/Smad1 pathway. It displays an expression pattern reminiscent of that of *BMP4* along the marginal and animal regions of early gastrulae. Expectedly, the *cis*-acting response elements for Smad1 and a cofactor OAZ as well as positive regulatory factors Xvent-2 and GATA2 have been identified in the promoter region of *Ventx1.1* ([@b8-bmb-52-403], [@b16-bmb-52-403]). In this study, we also identified Xcad2 as an activator of *Ventx1.1* transcription that directly occupied a response element in its promoter sequence ([Fig. 4E](#f4-bmb-52-403){ref-type="fig"}), which was distinct from that for Smad1, OAZ, or Xvent-2. Mutation of this response element significantly abrogated basal and Xcad2-induced activation of the −951-bp *Ventx1.1* promoter, which still contained intact response elements for Smad1, OAZ, and Xvent-2. As such, the contribution of the Xcad2-responsive element to peak activation of the *Ventx1.1* promoter would be highly significant. Our previous study has revealed that Xbra, a target of FGF signaling, also cooperates with Smad1 to up-regulate the activity of the *Ventx1.1* promoter in a synergistic manner ([@b7-bmb-52-403]). Expression of *Xcad2* and *Xvent-2* can be induced by not only BMP signal, but also by combined activity of Wnt and FGF signaling pathways ([@b3-bmb-52-403], [@b12-bmb-52-403], [@b17-bmb-52-403], [@b18-bmb-52-403]). Thus, it appears that transcriptional cofactors Xbra, Xcad2, and Xvent-2 can act as mediators of cross-talk between BMP and other signals such as Wnt and FGF in the control of *Ventx1.1* transcription. Given that expression patterns of *Ventx1.1* and its upstream regulators *Xbra*, *Xcad2*, and *Xvent-2* in *Xenopus* gastrulae are overlapped ([@b3-bmb-52-403]), these transcriptional cofactors appear to play roles in restricting *Ventx1.1* expression both spatially and temporally. On the other hand, Xbra, Xcad2, or Xvent-2 was unable to efficiently induce *Ventx1.1* expression in the absence of BMP signaling ([@b3-bmb-52-403], [@b9-bmb-52-403], [@b16-bmb-52-403]), indicating the necessity of their cooperation with basic regulatory factors activated by BMP signal. Taken together, these results suggest that these transcriptional factors primarily contribute to maximal activation rather than basal activity of *Ventx1.1* transcription.

It has been shown that Goosecoid acts as a repressor of *Ventx1.1* transcription to oppose its ventralizing activity ([@b19-bmb-52-403]). Consistently, a response element for Goosecoid is present in the *Ventx1.1* promoter, and overexpression of *Goosecoid* suppresses its activity ([@b8-bmb-52-403]). Since *Goosecoid* is expressed on the dorsal side of *Xenopus* early gastrulae, the absence of *Ventx1.1* transcription in that region might be primarily due to Goosecoid-mediated repression of its promoter activity. Notably, we observed that Ventx1.1 down-regulated its own transcription by binding to a response element within its own promoter ([Fig. 4E](#f4-bmb-52-403){ref-type="fig"}). An intriguing aspect of the Ventx1.1 response element in its own promoter is that this sequence is competitively co-occupied by Ventx1.1 and a transcriptional activator Xcad2. This feature suggests that negative auto-regulation of *Ventx1.1* transcription occurs in tissues where *Ventx1.1* is endogenously expressed such as the ventrolateral marginal region of *Xenopus* gastrulae. In addition, since Xcad2 is required for the peak activity of *Ventx1.1* promoter, it is reasonable to speculate that the inhibitory auto-regulation of *Ventx1.1* transcription might be a key regulatory mechanism to maintain *Ventx1.1* expression at a moderate level. Overexpression of *Ventx1.1* abolished the expression of endogenous *Ventx1.1* as well as of its upstream regulator *Xvent-2* ([Fig. 1](#f1-bmb-52-403){ref-type="fig"}), possibly resulting in significant decrease of *Ventx1.1* expression below moderate level. As shown in our ChIP-PCR assays ([Fig. 4](#f4-bmb-52-403){ref-type="fig"}), Ventx1.1 appeared to displace Xcad2 more easily from the co-occupied response element than Xcad2, suggesting a stronger association of Ventx1.1 with the promoter. This strong binding affinity of Ventx1.1 might ensure immediate control of its own expression in the presence of transcriptional activators such as Xcad2. In this respect, fine-tuning of relative cellular levels of Ventx1.1 and Xcad2 might play critical roles in the establishment of optimal level of *Ventx1.1* expression, contributing to proper dorsoventral patterning of early embryo. Of note, it has also been shown that Goosecoid can negatively control its own promoter activity for balanced organizer activity ([@b11-bmb-52-403]). Thus, Ventx1.1 and Goosecoid appear to repress each other, leading to their separate expression on the ventral and dorsal sides of embryo, and negatively regulate their own transcription to achieve appropriate levels of their respective expression.

MATERIALS AND METHODS
=====================

Embryo manipulation
-------------------

*Xenopus laevis* were obtained from the Korean *Xenopus* Resource Center for Research. Embryos were obtained by *in vitro* fertilization after induction of female frogs with 500 units of human chorionic gonadotropin (Sigma) as previously described ([@b20-bmb-52-403]). mRNAs and/or DNA constructs were injected into the animal pole region of one-cell stage embryos. For animal cap assays, animal cap explants were dissected from injected or uninjected embryos at stage 8 and incubated in L-15 medium to the desired stages for subsequent experiments.

Ventx1.1 (Xvent-1b, PV.1) genomic DNA and promoter constructs
-------------------------------------------------------------

Genomic library screening for the isolation of *Ventx1.1a* genomic DNA was previously described ([@b8-bmb-52-403]). A 3.8-kb DNA fragment from the library screening, which contained 2.5 kb of 5′-flanking region of *Ventx1.1*, was subcloned into pGL-2 basic plasmid (Promega) to produce a −2525-bp promoter construct. Serially-deleted *Ventx1.1* promoter constructs were generated by subcloning its promoter fragments, which were obtained from the −2525-bp construct by PCR amplification ([Supplementary Table 2](#s1-bmb-52-403){ref-type="supplementary-material"}), into a pGL-2 basic plasmid.

Site-directed mutagenesis
-------------------------

Mutagenesis was performed using Muta-Direct^TM^ site-directed mutagenesis kit (iNiRON) in accordance with manufacturer's instructions. Primers used for mutagenesis of VRE1 and VRE2 were as follows: VRE1, (forward) 5′-CAAAG AAGAGGAGG GGGGTCGCTGGGGCAA-3′ and (reverse) 5′-TTGCCCCAG CGACCCCCCTCCTCTTCTTTG-3′; VRE2, (forward) 5′-CATCC TGCTGGCGGGGGTTCATTCTAG CTG-3′ and (reverse) 5′-C AGCTAGAATGAACCCCCGCCAGCAGGATG-3′.

RNA synthesis
-------------

Capped synthetic mRNAs were *in vitro* generated using a MEGAscript kit (Ambion) according to manufacturer's instructions. Expression constructs *Flag-Ventx1.1* and *Myc-Xcad2* were linearized with *SacII* and *Asp718*, respectively, and their respective mRNAs were synthesized using SP6 RNA polymerase.

Chromatin Immunoprecipitation (ChIP) assay
------------------------------------------

For ChIP assay, embryos were injected at one-cell stage with *Flag-Ventx1.1* (0.5 ng/embryo) and *Myc-Xcad2* (1 ng/embryo) mRNA either alone or together, collected at stage 11 (100 embryos/sample) and processed according to published protocol ([@b21-bmb-52-403]). Anti-Flag (Sigma, F-1804) monoclonal antibody and anti-Myc (Santa Cruz, SC-789) polyclonal antibody were used to immunoprecipitate chromatin fragments. Normal rabbit IgG (Santa Cruz, SC-2027) and mouse IgG (Santa Cruz, SC-2025) were used as negative controls. Primers used for PCRs are listed in [Supplementary Table 2 and 3](#s1-bmb-52-403){ref-type="supplementary-material"}.

RNA isolation and RT-PCR
------------------------

Total RNA was isolated from whole embryos or animal caps using RNA-Bee reagent (TEL-TEST) and treated with DNase I to remove genomic DNA contamination. cDNAs were synthesized using SuperScript IV (Invitrogen) with 2 μg total RNA per reaction. PCRs were performed as follows: 30 seconds at 94°C, 30 seconds at 57°C and 30 seconds at 72°C; 20--26 cycles of amplification ([Supplementary Table 3](#s1-bmb-52-403){ref-type="supplementary-material"}).

Western blotting
----------------

Whole embryos were homogenized in lysis buffer containing phosphatase and protease inhibitors. Proteins were resolved on 12% SDS-PAGE. The following antibodies were used: anti-Flag monoclonal (Sigma, F-1804) and anti-Myc polyclonal (Santa Cruz, SC-805) primary antibodies, and anti-rabbit IgG (Santa Cruz, SC-789) and anti-mouse IgG (Stressgen, SAB-100) secondary antibodies. Protein bands were visualized using an ECL detection kit (GE healthcare).

Luciferase reporter assay
-------------------------

Luciferase reporter assays were carried out using luciferase assay system (Promega) according to the manufacturer's instructions. Five different groups of embryos (3 embryos/group) were harvested and homogenized in lysis buffer (10 μl/embryo). Embryo lysates (10 μl) were assayed with luciferase substrate (40 μl), and relative luciferase activity was determined by luminometer (EG &G, Berthold). Independent experiments were repeated at least three times.

Statistical analysis
--------------------

All data were analyzed using GraphPad Prism4. Statistical analysis was performed with one-way analysis of variance (ANOVA). A P value of less than 0.05 was considered statistically significant (\*\*P \< 0.01; \*\*\*P \< 0.001; n.s., not significant).

Nucleotide sequence accession number
------------------------------------

*Ventx1.1* cDNA sequence was deposited at GenBank (accession number: AF133122).
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![Ventx1.1 represses expression of ventral-specific genes. (A) One-cell stage embryos were injected in the animal pole region with *Flag-Ventx1.1* mRNA (500 pg), and animal caps were dissected from injected or uninjected embryos at stage 8 and cultured to stage 11.5 for RT-PCR analysis. *EF1α* serves as a loading control. WE, stage 11.5 whole embryo. AC, animal cap. −RT, control in the absence of reverse transcriptase. (B) Quantification of expression levels of ventral genes (normalized to *EF1α*) from three independent experiments for (A). Error bars indicates standard error (SE).](bmb-52-403f1){#f1-bmb-52-403}

![Identification of a Ventx1.1-responsive element (VRE) in its own promoter region. (A) Diagram of *Ventx1.1* promoter deletion constructs. The length that each promoter fragment extends upstream of the major *Ventx1.1* transcription initiation site is indicated at left. Each promoter fragment was fused to luciferase (LUC) reporter gene. (B--E) Embryos were injected at one-cell stage with wild-type or putative VRE-mutated *Ventx1.1* promoter deletion constructs alone or with *Flag-Ventx1.1* mRNA (500 pg) as indicated, cultured to stage 10.5 (B) or 11.5 (B--E), and harvested for luciferase reporter assays. All relative promoter activity data are shown as mean ± standard error (SE). (F) ChIP-PCR analysis showing the occupancy by Ventx1.1 of its own promoter region. *Ventx1.2*, a negative control for PCR, was amplified using its coding region-specific primers. IgG, a negative control IgG.](bmb-52-403f2){#f2-bmb-52-403}

![Xcad2 up-regulates *Ventx1.1* transcription by occupying VRE1. (A) Animal caps from embryos injected or not with *Flag-Ventx1.1* (500 pg) and/or *Myc-Xcad2* (1 ng) mRNA as indicated were subjected to RT-PCR analysis at stage 11.5. (B--E) One-cell stage embryos were injected with indicated combinations of −951-bp reporter, −951-bp-mVRE1 reporter, *Flag-Ventx1.1* (500 pg), and *Myc-Xcad2* (1 ng) and cultured to stage 11 for ChIP-PCR (C, D) or stage 11.5 for luciferase reporter assay (B, E). (D) Quantification of relative intensities of bands in lanes 2, 5, and 6 shown in (C).](bmb-52-403f3){#f3-bmb-52-403}

![Ventx1.1 and Xcad2 co-occupy *Ventx1.1* promoter region in competition with each other. (A--D) Embryos were injected with a combination of *Flag-Ventx1.1* (0.5 ng) and increasing doses of *Myc-Xcad2* (0.5, 1 ng) or *Myc-Xcad2* (1 ng) and increasing doses of *Flag-Ventx1.1* (0.25, 0.5 ng) as indicated and cultured to stage 11.5 for ChIP-PCR analysis. (B, D) represent quantification of relative intensities of bands in lanes 1, 2, and 3 in (A, C), respectively. (−), no injection of *Myc-Xcad2* or *Flag-Ventx1.1*. *Ventx2.1*, a negative PCR control, was amplified with its coding region-specific primers. (E) A proposed model for Ventx1.1 or Xcad2-mediated control of *Ventx1.1* transcription.](bmb-52-403f4){#f4-bmb-52-403}
